Tideglusib ( Noscira / Zeltia ) . Solanezumab ( Lilly ) y Bapinezumab ( J&J,Pfizer y Elan ) . Los 3 Farmacos con + Espectativas para Alzheimer World .

... Beyond the government initiatives, 2012 represents a pivotal year for AD drug development, especially in view of expected results from ongoing Phase 3 trials, including solanezumab by Eli Lilly & Co. (LLY), bapineuzumab by Johnson & Johnson (JNJ), Pfizer Inc. (PFE), and Elan Corporation plc (ELN), and tideglusib by Noscira/Grupo Zeltia.

...